Relmada Therapeutics (RLMD) Akcie Kurz
Relmada Therapeutics Kurz
Tržby Relmada Therapeutics klesaly o 28,4 % ročně za posledních 2 let na 5 129,00 USD. U Relmada Therapeutics je čistá marže -877,7 % dolů oproti -100,0 % před několika lety. Konsenzuální 12měsíční cílová cena pro Relmada Therapeutics je 11,00 USD, asi nad cenu o 165,7 %. Z 10 analytiků jich 9 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie Relmada Therapeutics
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model Relmada Therapeutics a analýza akcií
Nejčastější otázky týkající se akcie Relmada Therapeutics
Relmada Therapeutics Inc is a pharmaceutical company that focuses on developing and commercializing innovative therapies for various medical conditions. Their business model revolves around researching and developing novel drug candidates, acquiring intellectual property rights, conducting clinical trials, and seeking regulatory approvals for their innovative products. By leveraging their expertise in drug development, Relmada aims to address unmet medical needs and improve patients' quality of life. Through collaborations and strategic partnerships, the company strives to bring their innovative therapies to market and generate value for their stakeholders.
Relmada Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Relmada Therapeutics Inc in the market include companies such as Johnson & Johnson, Pfizer Inc, Novartis AG, and Eli Lilly and Company.
Relmada Therapeutics Inc is a pharmaceutical company specializing in the development and commercialization of novel therapies for various diseases. Founded in 2012, Relmada focuses on innovative solutions to address unmet medical needs and improve patients' lives. The company's research and development efforts primarily concentrate on central nervous system (CNS) disorders, including chronic pain, addiction, and rare diseases. Relmada Therapeutics Inc has successfully advanced several promising drug candidates through preclinical and clinical trials, demonstrating its commitment to delivering effective and safe treatments. With its dedication to scientific advancements, Relmada Therapeutics Inc is poised to make a significant impact in the evolving healthcare industry.
Relmada Therapeutics Inc has achieved several significant milestones. The company successfully completed Phase 2 trials for its lead product, d-Methadone, for the treatment of neuropathic pain. In addition, Relmada Therapeutics received Fast Track designation from the U.S. Food and Drug Administration (FDA) for d-Methadone, which expedites the development and review process. The company also completed a successful IPO, raising $65 million in gross proceeds. Relmada Therapeutics continues to advance its pipeline, focusing on innovative therapies for central nervous system (CNS) disorders. With its groundbreaking achievements, Relmada Therapeutics Inc has positioned itself as a key player in the pharmaceutical industry.
Relmada Therapeutics Inc primarily operates in the United States.
Relmada Therapeutics Inc represents values of innovation, commitment to patient wellbeing, and scientific excellence. The company is dedicated to developing novel therapies to address unmet medical needs. Relmada focuses on advancing research and developing cutting-edge treatments to improve patients' quality of life. Their corporate philosophy revolves around collaboration, ethical practices, and a patient-centric approach. Relmada Therapeutics Inc believes in fostering partnerships and leveraging scientific expertise to create transformative healthcare solutions. Through their dedication to innovation and commitment to advancing medical science, Relmada aims to make a meaningful impact in improving patient outcomes and addressing global healthcare challenges.
Analytici aktuálně stanovují průměrnou cílovou cenu 11,00 USD pro akcii Relmada Therapeutics (medián: 11,00 USD), tedy +165,7 % vůči poslední ceně. Konsensus vychází z 10 hodnocení analytiků.
10 analytiků aktuálně hodnotí akcii Relmada Therapeutics: 9 doporučuje koupit, 1 držet a 0 prodat. Pro rok 2026 analytici očekávají u Relmada Therapeutics tržby 10,00 Mil. USD a zisk na akcii -0,28 USD.
Při aktuálním kurzu se akcie Relmada Therapeutics obchoduje za 3,70 EUR (4,14 USD).
Akcie Relmada Therapeutics (RLMD) je kótována na 3 burzách, mimo jiné: NASDAQ (RLMD), Frankfurt (4E2.F), München (4E2.MU).
Relmada Therapeutics Inc. is a biopharmaceutical company specializing in the development of novel therapeutics for central nervous system (CNS) disorders. The company is headquartered in New York City and offers a wide range of products and services tailored to the needs of patients and medical professionals. Relmada Therapeutics' business model is based on identifying, developing, and marketing innovative therapeutics for brain disorders and other psychiatric illnesses. The company holds a number of patents for developing biological therapeutics targeting various molecules within the human body. It has established an extensive network of partnerships with leading scientific and medical institutions to conduct a variety of clinical studies that help demonstrate the efficacy and safety of its products. Relmada Therapeutics' portfolio includes a range of novel therapeutics that can be used to treat a variety of psychiatric disorders. The company specializes in the development of preparations for the treatment of pain, depression, and addiction. Its flagship product is REL-1017, which targets the glutamatergic receptor and is currently in phase 3 clinical trials for the treatment of depression. In addition to its product pipeline, Relmada Therapeutics also offers a comprehensive range of services for medical professionals and patients. The company has a team of experienced clinical experts who assist customers in developing individualized treatment plans tailored to the specific needs of each patient. Relmada Therapeutics has also built a wide range of partnerships and alliances with key players in the pharmaceutical industry and healthcare. These partnerships enable the company to further expand its product development activities and improve the global marketing of its therapeutics. Overall, Relmada Therapeutics is an innovative biopharmaceutical company focused on improving the treatment of psychiatric disorders. Its comprehensive portfolio of products and services for medical professionals and patients, its experienced clinical experts, and its strong partnerships with other key players in the industry make it a significant player in the global market for psychiatric medications.
Tržby očekávané za Relmada Therapeutics činí 10,00 Mil. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za Relmada Therapeutics činí -18,78 Mil. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Relmada Therapeutics je aktuálně -15,05. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Relmada Therapeutics.
Poměr ceny k tržbám (P/S) Relmada Therapeutics je aktuálně 28,26. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Relmada Therapeutics.
Score kvality pro Relmada Therapeutics je 2/10.
ISIN Relmada Therapeutics je US75955J4022. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN Relmada Therapeutics je A2PSZF. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker Relmada Therapeutics je RLMD. Symbol tickeru se používá k obchodování akcií Relmada Therapeutics na burze.
Relmada Therapeutics akcie
Relmada Therapeutics Peer Group
Relmada Therapeutics Ticker
Relmada Therapeutics FIGI
Všechny fundamentální údaje o Relmada Therapeutics v podrobné analýze
Naše analýzy akcií společnosti Relmada Therapeutics zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Relmada Therapeutics. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: